Unicycive Therapeutics Reports Full Year 2025 Financial Results and Provides Significant Business Updates

Key Highlights for Investors

• Oxylanthanum Carbonate (OLC) NDA Resubmission Under FDA Review:
  Unicycive Therapeutics announced that the U.S. FDA has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), an investigational oral phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The Prescription Drug User Fee Act (PDUFA) target action date is set for June 29, 2026.
• Commercial Launch Preparations Underway:
  The company is actively preparing for potential commercial launch of OLC, anticipated in Q3 2026, by strengthening its commercial infrastructure and advancing market readiness initiatives.
• Financial Strength and Runway:
  As of March 30, 2026, Unicycive reported unaudited cash, cash equivalents, and marketable securities totaling \$54.9 million, with an operational runway expected to extend into 2027.
• Significant Reduction in R&D Expenses:
  Research and Development expenses decreased sharply to \$9.1 million for 2025, down from \$20.0 million in 2024, mainly due to reduced drug development and clinical trial costs.
• Increased General and Administrative Expenses:
  General and Administrative expenses rose to \$20.4 million in 2025 from \$12.1 million in 2024, reflecting increased investments in consulting, professional services, and commercial launch preparations.
• Improvement in Net Loss and Other Income:
  Net loss attributable to common stockholders narrowed to \$26.6 million (\$1.67 per share) in 2025 from \$37.8 million (\$5.65 per share) in 2024, primarily due to lower R&D costs. The company also reported other income of \$3.0 million (versus a \$4.6 million expense in 2024) driven by a decrease in the fair value of its warrant liability.
• Strong Balance Sheet and Shareholder Equity:
  As of December 31, 2025, total assets stood at \$49.1 million, and total stockholders’ equity was \$30.2 million, up from \$7.4 million a year earlier.
• Clinical and Regulatory Update:
  The NDA for OLC is backed by three clinical studies (including Phase 1, bioequivalence, and tolerability studies) and comprehensive preclinical and CMC data. The FDA has not raised concerns regarding preclinical, clinical, or safety data in the original NDA submission. The resubmission in December 2025 was based on improvements at the third-party manufacturing site.
• Pipeline Update:
  Unicycive’s second asset, UNI-494, is being developed for acute kidney injury-related conditions and has received Orphan Drug Designation (ODD) for preventing Delayed Graft Function in kidney transplant patients. UNI-494 has completed a Phase 1 dose-ranging safety study.

Potential Share Price Catalysts and Risks

• Upcoming FDA Decision: The acceptance and review of OLC’s NDA, with a defined PDUFA date, presents a major regulatory catalyst for the company. Approval could significantly affect the share price, as OLC addresses a large unmet need in the CKD population, where nearly 75% of U.S. dialysis patients have uncontrolled hyperphosphatemia.
• Preparation for Commercialization: Ongoing investments in commercial infrastructure signal management’s confidence in OLC’s prospects and readiness for market entry, which could impact valuation.
• Financial Health: The strengthened balance sheet and extended cash runway reduce financing risk in the near term, which is positive for investor sentiment.
• Risk Factors: Investors should note that clinical development and regulatory approvals remain uncertain and lengthy processes, and there are risks related to manufacturing, market acceptance, and competition. The company also highlights potential risks from dependence on third parties and possible regulatory noncompliance.

Detailed Financial Summary

Conclusion

Unicycive Therapeutics is at a pivotal juncture, with its lead asset OLC under active FDA review and potential for U.S. market approval and launch later this year. The company’s strengthened balance sheet, reduced R&D spend, and preparations for commercialization position it well for the next phase. The upcoming PDUFA date is a key catalyst that could significantly move the stock, while ongoing risks inherent to biotech development remain. Investors should monitor FDA communications, commercialization progress, and ongoing pipeline developments for UNI-494.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The biotechnology sector involves significant risks, including but not limited to clinical, regulatory, and commercial uncertainties. Past performance is not indicative of future results.

View Unicycive Therapeutics, Inc. Historical chart here